Histoire du monastère de Selby, dépendance de Saint-Germain d'Auxerre.

Donné par Châtre de Cangé en 1733, après la vente de ses manuscrits à la Bibliothèque du roi; cf. Catalogue des livres du Cabinet de M..., Paris, 1733, description à la main ajoutée sur les derniers feuillets de garde de plusieurs exemplaires de ce catalogue "Notice de quelques manuscrits d'elite qui n'étoient pas compris dans le catalogue et que M. du Cangé a donnés au roi... Histoire du monastère de Selby, ordre de St Benoît, dans la province d'Yorc. Ce vol. étoit sans inscription et sans n° et vient pourtant du fond de du Cangé"; Delisle, Cab. des mss., I, 411-412; n° 143 de la liste des manuscrits de Cangé établie par Méon; — ex-libris (XVIIe s.)"Monasterii S. Germain Autisiodorensis" de l'abbaye de Saint-Germain d'Auxerre (1), cf. Delisle, Cab. des mss., II, 405.

Desempenho produtivo de nespereiras enxertadas em marmeleiro 'Portugal'

O objetivo deste trabalho foi comparar o desempenho produtivo de cinco seleções de nespereiras enxertadas em marmeleiro e na própria nespereira. Foram utilizadas cinco seleções de nespereira: IAC 966-23, IAC 265-66, IAC 1467-25, Mizauto (IAC 167-4) e Mizumo (IAC 1567-411), enxertadas em estacas enraizadas de marmeleiro 'Portugal' (distribuídas no campo no espaçamento 4x2 m, densidade de 1.250 plantas ha-1) e em plântulas de nespereiras (em espaçamento 7x4 m, densidade de 357 plantas ha-1). O experimento foi conduzido no Município de Monte Alegre do Sul, SP. Nos três anos após o plantio das mudas no campo, avaliou-se a produção (quilograma e número de frutos por planta), massa média dos frutos (g) e a produtividade (Mg ha-1). Calculou-se a média dos quatro anos consecutivos de produção. A seleção IAC 265-66 apresentou o melhor desempenho em porta-enxertos de marmeleiro e da própria nespereira. Apesar da menor produção, não houve diferença na produtividade entre os porta-enxertos do marmeleiro e da própria nespereira. O emprego de porta-enxertos de marmeleiro para nespereiras é uma opção para reduzir o porte e, conseqüentemente, facilitar tratos culturais.

Identification of the minimal promoter region of the mouse NKX5-3, a transcription factor implicated in eye development.

Early ocular development is controlled by a complex network of transcription factors, cell cycle regulators, and diffusible signalling molecules. Together, these molecules regulate cell proliferation and apoptosis, and specify retinal fate. NKX5-3 is a homeobox transcription factor implicated in eye development. The analysis of the 5'-flanking region of the mouse Nkx5-3 gene revealed a predicted TATA-less promoter sequence between -416 and -166 of the translation start site. To functionally characterise Nkx5-3 promoter activity, serial deletions of the promoter sequence were introduced in pGL-3 basic vector and promoter activity of these 5'- and 3'-deleted constructions was tested in HeLa and CHO cells. Transactivation assays identified a region between -350 and -296 exhibiting promoter-like activity. Combined analysis by deletions and point mutations showed that this sequence, containing multiple Sp1 binding sites was necessary to promote transcriptional activity. Binding of Sp1 to this region was confirmed by electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation, using an antibody specific for Sp1. Altogether, these results demonstrated that the immediate upstream region of Nkx5-3 gene possessed a strong intrinsic promoter activity in vitro, suggesting a potential role in Nkx5-3 transcription in vivo.

Rose de mai : légendes parisiennes / par Louis Lazare ; par P. Creton

Comprend : Geoffroy l'Asnier ; Entre deux canons

Methionine-321 in the C-terminal alpha-helix of catabolic ornithine carbamoyltransferase from Pseudomonas aeruginosa is important for positive homotropic cooperativity.

Pseudomonas aeruginosa has a pair of distinct ornithine carbamoyltransferases. The anabolic ornithine carbamoyltransferase encoded by the argF gene catalyzes the formation of citrulline from ornithine and carbamoylphosphate. The catabolic ornithine carbamoyltransferase encoded by the arcB gene promotes the reverse reaction in vivo; although this enzyme can be assayed in vitro for citrulline synthesis, its unidirectionality in vivo is determined by its high concentration at half maximum velocity for carbamoylphosphate ([S]0.5) and high cooperativity toward this substrate. We have isolated mutant forms of catabolic ornithine carbamoyltransferase catalyzing the anabolic reaction in vivo. The corresponding arcB mutant alleles on a multicopy plasmid specifically suppressed an argF mutation of P. aeruginosa. Two new mutant enzymes were obtained. When methionine 321 was replaced by isoleucine, the mutant enzyme showed loss of homotropic cooperativity at physiological carbamoylphosphate concentrations. Substitution of glutamate 105 by lysine resulted in a partial loss of the sigmoidal response to increasing carbamoylphosphate concentrations. However, both mutant enzymes were still sensitive to the allosteric activator AMP and to the inhibitor spermidine. These results indicate that at least two residues of catabolic ornithine carbamoyltransferase are critically involved in positive carbamoylphosphate cooperativity: glutamate 105 (previously known to be important) and methionine 321. Mutational changes in either amino acid will affect the geometry of helix H2, which contains several residues required for carbamoylphosphate binding.

Durée et structure du sommeil et risques métaboliques et cardiovasculaires = [Sleep structure and cardiometabolic disorders]

Introduction : Plusieurs études épidémiologiques et de laboratoire basées sur des estimations subjectives de la durée et de la qualité du sommeil suggèrent que celles-ci pourraient être associées à une augmentation du risque de troubles métaboliques ou cardiovasculaires. Objectif : Dans cette étude nous avons examiné les associations entre les caractéristiques du sommeil évaluées objectivement par Polysomnographie (PSG) et le syndrome métabolique ainsi que ses composants (hypertension, diabète, obésité). Matériel et méthodes : Nous avons analysé les données de 2162 sujets de la population générale (dont le 51.2% étaient des femmes, âge moyen : 58.4±11.1 ans, fourchette d'âge: 40.5-84.4) qui ont participé à l'étude Hypnolaus. Tous les sujets ont eu une évaluation clinique et biologique et ils ont bénéficié d'une PSG complète à domicile. Résultats : Les analyses univariées ont montré que les sujets présentant un syndrome métabolique avaient une diminution du temps total de sommeil, du sommeil lent profond, du sommeil paradoxal et de l'efficacité du sommeil, ainsi qu'une augmentation de l'index de microéveils par rapport aux sujets qui n'avaient pas un syndrome métabolique. Nous avons aussi trouvé des différences significatives de la structure du sommeil en fonction de la présence ou de l'absence d'hypertension, de diabètes et de surpoids/obésité. Cependant, ces différences s'atténuent après ajustement pour des facteurs confondants (âge, genre, tabagisme, prise d'alcool, activité physique, médicaments qui affectent le sommeil, dépression, santé globale et indice de masse corporelle). Seules des différences marginales, non statistiquement significatives, persistaient dans le modèle multiajusté et après stratification en fonction de la présence de troubles respiratoires au cours du sommeil. Conclusions: Dans cet échantillon de la population générale nous avons mis en évidence des associations significatives entre la structure du sommeil et le syndrome métabolique ainsi que ses composants. Cependant, ces associations ne sont pas indépendantes des autres facteurs de risque cardiométabolique connus. Nous en concluons que les variations normales de la durée et de la structure du sommeil contribuent peu ou pas au syndrome métabolique et ses troubles associés.

De bello Italico adversus Gothos ([Reprod.])

Collection : Italian books before 1601 ; 411.3

Aktiivisten magneettilaakereiden tilasäädön mallinnus ja simulointi

Aktiivisten magneettilaakereiden avulla on mahdollista kannatella ferromagneettisia kappaleita, kuten sähkökoneiden roottoreita, ilman fyysistä kontaktia. Magneettilaakerit tarjoavat monia etuja, kuten esimerkiksi kitkattomuuden, verrattuina perinteisiin mekaanisiin laakereihin. Nämä edut vielä korostuvat suurnopeuskäytöissä, jotka ovat magneettilaakereiden pääasiallisia käyttökohteita. Tässä työssä esitellään magneettilaakereihin liittyvät erusteoriat ja niiden sovellustavat. Tämän jälkeen tarkastellaanmagneettilaakereiden kanssa käytettäviä säätöratkaisuja ja esitetään niille soveltuvat viritysmenetelmät. Teorioiden pohjalta rakennetaan täydellinen magneettilaakerijärjestelmän simulointimalli säätöratkaisuineen ja suoritetaan järjestelmän toimintaa kuvaavia simulointeja. Simuloinneissa saadut tulokset pyritään vielä varmentamaan suorittamalla mittauksia koelaitteistolla ja vertaamalla saatuja tuloksia keskenään.

Artérite de Horton: recommandations Lausannoises de prise en charge [Giant cell arteritis: guidelines of the University Hospital of Lausanne].

L'artérite de Horton (AH), une vasculite subaiguë à chronique, est la plus fréquente des vasculites systémiques dans la population âgée de plus de 50 ans. L'absence de critères diagnostiques univoques, ajoutée au fait que le tableau clinique souvent complexe nécessite une prise en charge multidisciplinaire, conduit assez régulièrement à un retard thérapeutique. Il s'agit pourtant d'une maladie nécessitant un traitement urgent en raison du risque de cécité. Cet article présente une revue de l'AH et se conclut par des recommandations institutionnelles lausannoises concernant le diagnostic, la thérapie et la prise en charge multidisciplinaire. Giant cell arteritis (GCA) is a subacute/chronic vasculitis and represents the most common form of systemic vasculitis in people over the age of 50 years. The absence of clear and specific diagnostic criteria with the highly variable clinical presentation is a diagnostic challenge requesting a multidisciplinary approach. Yet, GCA is an emergency and the treatment must be initiated very rapidly due to the risk of blindness. This article presents a review of GCA as well as the diagnostic and therapeutic institutional guidelines of the University Hospital of Lausanne.

Mujeres víctimas de trata en prisión en España

La trata de seres humanos constituye uno de los fenómenos criminales emergentes en la sociedad globalizada. La comunidad internacional emprendió una estrategia global contra este fenómeno a comienzos de los 2000, adoptando una política esencialmente criminalizadora. Más contemporáneamente, las políticas emprendidas contra este fenómeno pretenden abordarlo integralmente, incidiendo también en la prevención y esencialmente en la protección de las víctimas, que pasa por su identificación como tales. El Estado español ha efectuado en los últimos dos años esfuerzos para alcanzar los estándares internacionalmente establecidos para luchar contra este fenómeno. Sin embargo, el estudio empírico que aquí se presenta muestra como en el plano aplicativo queda todavía mucho por hacer. Se trata de un estudio cualitativo efectuado con 45 mujeres recluidas en dos Centros penitenciarios españoles algunas de las cuales han sido objeto de una grave victimización institucional. En el caso de 10 de estas mujeres, identificadas como víctimas de trata en este estudio, al padecimiento del proceso victimizador propio de haber sufrido los efectos de la trata de seres humanos, se suma la victimización integrada no sólo por no haber sido detectadas como víctimas de este fenómeno por el sistema, sino además por haber sido condenadas y hallarse recluidas cumpliendo condena por la comisión de un delito producida en fase de explotación del proceso de trata.

Growth and production of irrigated vitória pineapple grown in semi-arid conditions

This study aimed to evaluate the growth characteristics of irrigated Vitória pineapple plants grown in semi-arid conditions and determine its developmental stages based on those characteristics. It was used a randomized block design with four replicates. The experimental treatments were: plant harvest at 270, 330, 390, 450, 510, 570, 690, 750, and 810 days after planting (DAP). The following variables were determined: plant height, stem diameter, D-leaf length, D-leaf fresh and dry mass, biomass production of plants and plant parts (organs), and vegetative biomass. Five phenological stages are proposed based on vegetative biomass production: < 20% biomass production (V1); 21-40% (V2); 41-60% (V3); 61-80% (V4); and > 80% (V5). The maximum growth rate for plant height, D-leaf length, and stem diameter was observed at the end of the phenological stage V1 (390-411 DAP), and at the end of stage V5 these plant traits had average values of 106, 82, and 7 cm, respectively. The maximum biomass accumulation rates were observed at stages V4 and V5, resulting in a final fruit yield and total fresh biomass of 72 t ha-1 and 326 t ha-1, respectively. Finally, we estimated that 80% of the accumulated biomass may remain in the field after fruit and slip harvest, and could be incorporated as plant residue into the soil.

Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study.

BACKGROUND: In Switzerland, patients may undergo "blood tests" without being informed what these are screening for. Inadequate doctor-patient communication may result in patient misunderstanding. We examined what patients in the emergency department (ED) believed they had been screened for and explored their attitudes to routine (non-targeted) human immunodeficiency virus (HIV) screening. METHODS: Between 1st October 2012 and 28th February 2013, a questionnaire-based survey was conducted among patients aged 16-70 years old presenting to the ED of Lausanne University Hospital. Patients were asked: (1) if they believed they had been screened for HIV; (2) if they agreed in principle to routine HIV screening and (3) if they agreed to be HIV tested during their current ED visit. RESULTS: Of 466 eligible patients, 411 (88%) agreed to participate. Mean age was 46 ± 16 years; 192 patients (47%) were women; 366 (89%) were Swiss or European; 113 (27%) believed they had been screened for HIV, the proportion increasing with age (p ≤0.01), 297 (72%) agreed in principle with routine HIV testing in the ED, and 138 patients (34%) agreed to be HIV tested during their current ED visit. CONCLUSION: In this ED population, 27% believed incorrectly they had been screened for HIV. Over 70% agreed in principle with routine HIV testing and 34% agreed to be tested during their current visit. These results demonstrate willingness among patients concerning routine HIV testing in the ED and highlight a need for improved doctor-patient communication about what a blood test specifically screens for.

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

BACKGROUND: The ongoing Ebola outbreak led to accelerated efforts to test vaccine candidates. On the basis of a request by WHO, we aimed to assess the safety and immunogenicity of the monovalent, recombinant, chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine (ChAd3-EBO-Z). METHODS: We did this randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a trial at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Participants (aged 18-65 years) were randomly assigned (2:2:1), via two computer-generated randomisation lists for individuals potentially deployed in endemic areas and those not deployed, to receive a single intramuscular dose of high-dose vaccine (5 × 10(10) viral particles), low-dose vaccine (2·5 × 10(10) viral particles), or placebo. Deployed participants were allocated to only the vaccine groups. Group allocation was concealed from non-deployed participants, investigators, and outcome assessors. The safety evaluation was not masked for potentially deployed participants, who were therefore not included in the safety analysis for comparison between the vaccine doses and placebo, but were pooled with the non-deployed group to compare immunogenicity. The main objectives were safety and immunogenicity of ChAd3-EBO-Z. We did analysis by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT02289027. FINDINGS: Between Oct 24, 2014, and June 22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo (n=20). Participants were followed up for 6 months. No vaccine-related serious adverse events were reported. We recorded local adverse events in 30 (75%) of 40 participants in the high-dose group, 33 (79%) of 42 participants in the low-dose group, and five (25%) of 20 participants in the placebo group. Fatigue or malaise was the most common systemic adverse event, reported in 25 (62%) participants in the high-dose group, 25 (60%) participants in the low-dose group, and five (25%) participants in the placebo group, followed by headache, reported in 23 (57%), 25 (60%), and three (15%) participants, respectively. Fever occurred 24 h after injection in 12 (30%) participants in the high-dose group and 11 (26%) participants in the low-dose group versus one (5%) participant in the placebo group. Geometric mean concentrations of IgG antibodies against Ebola glycoprotein peaked on day 28 at 51 μg/mL (95% CI 41·1-63·3) in the high-dose group, 44·9 μg/mL (25·8-56·3) in the low-dose group, and 5·2 μg/mL (3·5-7·6) in the placebo group, with respective response rates of 96% (95% CI 85·7-99·5), 96% (86·5-99·5), and 5% (0·1-24·9). Geometric mean concentrations decreased by day 180 to 25·5 μg/mL (95% CI 20·6-31·5) in the high-dose group, 22·1 μg/mL (19·3-28·6) in the low-dose group, and 3·2 μg/mL (2·4-4·9) in the placebo group. 28 (57%) participants given high-dose vaccine and 31 (61%) participants given low-dose vaccine developed glycoprotein-specific CD4 cell responses, and 33 (67%) and 35 (69%), respectively, developed CD8 responses. INTERPRETATION: ChAd3-EBO-Z was safe and well tolerated, although mild to moderate systemic adverse events were common. A single dose was immunogenic in almost all vaccine recipients. Antibody responses were still significantly present at 6 months. There was no significant difference between doses for safety and immunogenicity outcomes. This acceptable safety profile provides a reliable basis to proceed with phase 2 and phase 3 efficacy trials in Africa. FUNDING: Swiss State Secretariat for Education, Research and Innovation (SERI), through the EU Horizon 2020 Research and Innovation Programme.